BioStock: Cereno Scientific adds new drug candidate to development pipeline

Cereno Scientific’s collaboration with the top-ranked University of Michigan bears fruit once again with the signing of a new agreement for the development of the preclinical drug candidate CS585 within cardiovascular diseases. The preclinical development will be done at the University under the supervision of Dr Michael Holinstat, and the new agreement also includes the successful transition to a phase I clinical programme.

Read the full article at biostock.se:

https://www.biostock.se/en/cereno-scientific-adds-new-drug-candidate-to-development-pipeline/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se